Evidence map›Paper›PMID 40257595›Full record

ArticleHeart and vessels2025

Characteristics of cardiac rehabilitation progress during hospitalization and in-hospital outcomes after mitral transcatheter edge-to-edge repair.

Kentaro Hori, Atsuko Nakayama, Shinya Tajima, Ruka Kanazawa, Kotaro Hirakawa, Yuichi Adachi, Yuki Izumi, Ryosuke Higuchi, Itaru Takamisawa, Mamoru Nanasato and 1 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Heart and vessels, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Kentaro HoriDepartment of Rehabilitation, Sakakibara Heart Institute, 3-16-1 Asahi-cho, Fuchu-shi, Tokyo, 183-0003, Japan. khori@shi.heart.or.jp.ORCID http://orcid.org/0000-0003-3376-0455
Atsuko NakayamaDepartment of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
Shinya TajimaDepartment of Rehabilitation, Sakakibara Heart Institute, 3-16-1 Asahi-cho, Fuchu-shi, Tokyo, 183-0003, Japan.
Ruka KanazawaDepartment of Rehabilitation, Sakakibara Heart Institute, 3-16-1 Asahi-cho, Fuchu-shi, Tokyo, 183-0003, Japan.
Kotaro HirakawaDepartment of Rehabilitation, Sakakibara Heart Institute, 3-16-1 Asahi-cho, Fuchu-shi, Tokyo, 183-0003, Japan.
Yuichi AdachiDepartment of Rehabilitation, Sakakibara Heart Institute, 3-16-1 Asahi-cho, Fuchu-shi, Tokyo, 183-0003, Japan.
Yuki IzumiDepartment of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
Ryosuke HiguchiDepartment of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
Itaru TakamisawaDepartment of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
Mamoru NanasatoDepartment of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
Mitsuaki IsobeSakakibara Heart Institute, Tokyo, Japan.

Funding

Sakakibara Heart Institute H-35-2023
6 · The paper itself

Abstract

Mitral regurgitation is a prevalent cardiac valvular disease, and its incidence is increasing with the aging population. While surgical intervention has traditionally been the standard treatment for this disease, in Japan, mitral transcatheter edge-to-edge repair (M-TEER) has emerged as a less invasive alternative since 2018. M-TEER demonstrates promising outcomes in reducing postoperative complications and shortening hospital stays. However, scarce data on cardiac rehabilitation (CR) following M-TEER is available. Therefore, in this study, we aimed to investigate the characteristics of CR progress during hospitalization and in-hospital outcomes following M-TEER. This single-center, retrospective cohort study involved 244 patients who underwent M-TEER at the Sakakibara Heart Institute between April 2018 and March 2023. Data on progress in CR and in-hospital outcomes, including hospitalization-associated disability (HAD), rate of return to home, and hospitalization that extended beyond 30 days after M-TEER, were collected. After excluding patients who met the exclusion criteria-including conversion to surgical mitral valve replacement or the absence of CR during hospitalization-233 patients were included in the analysis. The patients' median age was 81 years, with 48.5% being female. In 43% of cases, the hospitalizations were unplanned. Ambulation was initiated at a median of 1 day after M-TEER, with 88.4% of patients being able to commence ambulation as early as 2 days after M-TEER. However, only 19.3% engaged in aerobic exercise using equipment in the CR room. The median length of stay following M-TEER was 6 days, with 4.7% of hospitalizations resulting in a stay of 30 days or more. Ultimately, 90.6% of patients were discharged home, with an incidence of HAD of 9.9%. Compared to the planned hospitalization group, the unplanned hospitalization group had a significantly lower rate of early postoperative ambulation (planned hospitalization group: 97.7% vs. unplanned hospitalization group: 76.2%, p < 0.01), a higher proportion of patients with hospital stays exceeding 30 days (0% vs. 10.9%, p < 0.01), a lower rate of home discharge (98.5% vs. 80.2%, p < 0.01), and an increased incidence of HAD (0.8% vs. 22.2%, p < 0.01). M-TEER provides a minimally invasive treatment option for mitral regurgitation with favorable early rehabilitation and in-hospital outcomes, particularly in planned hospitalization. However, for unplanned hospitalizations, inpatient outcomes were poor.

Indexed as

Cardiac CatheterizationCardiac RehabilitationHeart Valve Prosthesis ImplantationHospitalizationMitral ValveMitral Valve InsufficiencyAgedAged, 80 and overFemaleFollow-Up StudiesHumansJapanLength of StayMaleRecovery of FunctionRetrospective StudiesCardiac rehabilitationIn-hospital outcomeMitral transcatheter edge-to-edge repairMitral valve regurgitation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.